Junova Bio Completes Tens of Millions RMB Pre-A Financing to Accelerate Clinical Promotion of Leading Oncology Molecular Diagnostic Products

VCBeat has learned that on November 16, Shanghai Junyuan Biotechnology Co., Ltd. (“Junyuan Biotech”) announced the completion of its Pre-A financing round, raising tens of millions of yuan. The round was led by Shenzhen Jinsheng Equity Investment Management Co., Ltd. (“Jinsheng Investment”). The funds will be used for the clinical registration and filing of its first blockbuster tumor molecular diagnostic product, clinical promotion of the product in domestic and international markets, and the research and development of innovative technologies and products across multiple pipelines. Previously, Junyuan Biotech had secured tens of millions of yuan in angel financing in September 2021.

Junyuan Biotech’s core team boasts decades of R&D and industry experience in drug development, molecular diagnostics, genomics, and artificial intelligence. By continuously increasing R&D investment and driving product innovation through technological breakthroughs, the company has independently developed the internationally leading J-STAR molecular diagnostics platform. This platform addresses clinical pain points and challenges in molecular diagnostics through foundational technological innovations. Combining the advantages of PCR and high-throughput sequencing platforms, J-STAR meets future demands for cutting-edge clinical testing and is widely applied in precision oncology treatment and recurrence monitoring. Its molecular diagnostic products under development are poised to fill multiple gaps in the market.

Junyuan Biotech has been in operation for less than two years. Grounded in the present while looking toward the future, the company is advancing steadily in accordance with its established strategic plan. It has currently been listed as a National Technology-based Small and Medium-sized Enterprise, with more than 20 patents and software copyrights applied for or granted. This year, the company’s R&D center and production base, spanning several thousand square meters at its headquarters in Zhangjiang Science City, passed quality certification and officially commenced operations. Multiple molecular diagnostic products for oncology and infectious diseases have obtained EU CE marking, enabling expansion into international markets and marking a new stage in the company’s commercialization process.

This year, the state has introduced a series of healthcare reform policies to support and encourage the development of the innovative medical industry, explicitly excluding innovative medical devices from the centralized procurement catalog for the time being, thereby providing broad market opportunities for technology-driven enterprises. Junyuan Biotechnology will remain committed to its mission, seize the opportunities of the times, and develop more high-value products tailored to national conditions in the post-pandemic era, so as to better serve hospitals at all levels and patients across the country.

Following this round of financing, the company will accelerate the expansion of its product pipeline, establish a diversified portfolio of leading products, and achieve cross-cancer integration of oncology diagnostic solutions. It will strengthen collaborations with clinical experts and pharmaceutical companies to promote clinical observational studies of novel biomarkers, driving breakthrough innovations in precision medical diagnostics. This will enable patients to access high-quality medical products and services, leveraging cutting-edge technology to precisely safeguard health and utilizing leading products to uphold quality of life.

Dr. Zhou Wengang, Founder and Chairman of Junyuan Bio“Junyuan Biologics is honored to have earned the recognition and support of our investors. Amid growing downward pressure on the global economy this year and a period of structural adjustment in the biopharmaceutical industry, Junyuan Biologics remains committed to clinical value as its guiding principle, aligns with national healthcare reform trends, and focuses on achieving breakthroughs in cutting-edge molecular diagnostics technologies as well as translating and developing innovative clinical products. Together with our partners, we are actively advancing regulatory registration and approval for our product pipeline and promoting commercialization in both domestic and international markets. By establishing a leading presence in niche sectors such as oncology and infectious diseases, we aim to seize opportunities and pursue long-term sustainable development, providing patients with accessible, innovative precision diagnostic products, and contributing to the effort of positioning China’s molecular diagnostics industry as a global leader.”

Yang Wulin, Founding Partner, Chairman, and General Manager of Jinsheng Investment“The innovative medical device industry is a sector that has long been supported by national policies and is closely related to people’s lives. Relying on its independently developed molecular diagnostics technology platform, Junyuan Bio has created globally leading tumor molecular diagnostic products in its niche segment, resolving critical technological bottlenecks in clinical practice. The clinical application prospects for these products are extremely broad. We are delighted to move forward together with Junyuan Bio and look forward to the company staying true to its original mission, achieving rapid growth, and accelerating the widespread clinical adoption of its high-tech, high-quality products to benefit more patients in China and around the world.”

Shenzhen Jinsheng Equity Investment Management Co., Ltd. is a private asset management platform specializing in equity investment (VC and PE) within China. Leveraging its shareholders’ robust industrial backgrounds, the company maintains a sustained focus on biomedicine and high-end manufacturing, prioritizing investments in industries encouraged by the state and characterized by significant market potential. To date, the company has invested in several high-quality biomedical enterprises, including Genetron Health (Zhenmai Bio), Ance Diagnostic, Nuwa Life, and WuXi Biologics’ joint venture, WuXi Bioray. Zhengzhou Antu Industrial Group Co., Ltd., a shareholder in the Jinsheng Investment Medical Fund, is the controlling shareholder of Autobio Diagnostics. As the first in vitro diagnostics (IVD) R&D and manufacturing enterprise listed on China’s Main Board, Autobio Diagnostics provides comprehensive solutions and integrated services for medical laboratories.